BYSI
BeyondSpring Inc.stockNASDAQ
beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin's potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.63 | 2026-11-06 | -2.72% | 3.337 |
| 1M | 0.61 | 2026-10-13 | +0.38% | 0.667 |
| 3M | 1.00 | 2026-08-13 | -38.87% | -0.076 |
| 6M | 1.45 | 2026-05-13 | -58.00% | 0.455 |
| 1Y | 2.06 | 2025-11-13 | -70.44% | 0.737 |
| 2Y | 1.85 | 2024-11-13 | -67.08% | — |
| 5Y | 14.80 | 2021-11-12 | -95.89% | 0.813 |
BeyondSpring Inc. (NASDAQ:BYSI) stock price today is $0.61, and today's volume is 33,174. BYSI is up 1.331% today. The 30 day average volume is 118,468. BYSI market cap is $25.04M with 41.12M shares outstanding.